drugset / Trial / NCT06650007

the Efficacy and Safety of HRS9531 Injection in Subjects With Type 2 Diabetes, Inadequately Controlled With Diet and Exercise Alone

NCT06650007

Phase 3 Completed 218 enrolled Fujian Shengdi Pharmaceutical Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objective of this study is to evaluate the effectiveness of HRS9531 compared to placebo in controlling blood glucose levels after 36 weeks of treatment

Timeline

Start
2024-11-08
Primary completion
2026-01-21
Completion
2026-06-12

Drugs

EvaluationDrugModalityDoseRoute
Subject HRS9531 Unknown